Going Deeper on Atopic Dermatitis
Pathophysiology to the Management of Moderate-to-Severe Disease
Meeting Slides
eBook Reader
 |
| Apple iBooks |
Clinical Practice Guidelines
Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.
Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.
Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349
Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233
Patient Resources
American Academy of Dermatology (AAD)
Founded in 1938, the AAD is the largest dermatology group in the United States. The ADD represents most practicing dermatologists in the United States and a growing number of international dermatologists.
International Eczema Council
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.
National Eczema Association
The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The mission of NIAMS is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.
Clinical Assessment Tools
Eczema Area and Severity Index (EASI)
EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe). (Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18).
Investigator Global Assessment (IGA)
The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials. (Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294).
Scoring Atopic Dermatitis (SCORAD)
SCORAD is a clinical tool used to assess the extent and severity of eczema. (Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.)
Suggested Readings
Management of difficult-to-treat atopic dermatitis.
Arkwright PD, et al. J Allergy Clin Immunol Pract. 2013;1(2):142-151
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. May 2017. [Epub ahead of print].
Translating atopic dermatitis management guidelines into practice for primary care providers.
Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565.
Persistence of mild to moderate atopic dermatitis.
Margolis JS, et al. JAMA Dermatol. 2014;150(6):593-600.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, et al. J Am Acad Dermatol. 2016;75(3):494-503.
Serious complications from staphylococcal aureus in atopic dermatitis.
Patel D, Jahnke MN. Ped Dermatol. 2015;32(6):792-796.
Anti-interleukin-31 receptor A antibody for atopic dermatitis.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.
Simpson EL, et al. J Am Acad Dermatol. 2016;74(3):491-498
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Eczema and cardiovascular risk factors in 2 US adult population studies.
Silverberg JI, Greenland P. J Allergy Clin Immunol. 2015;135(3):721-728.
Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.
Silverberg JI, Silverberg NB. J Allergy Clin Immunol. 2014;133(4):1041-1047.
The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.
Whiteley J, et al. Curr Med Res Opin. 2016;32(10):1645-1651
Interactive PresentationClinical Insights Into Atopic Dermatitis Pathogenesis
Narrated by Jeffrey M. Weinberg, MD
Patient Perspectives
Narrated by Jeffrey M. Weinberg, MD
Looking Beneath the Surface: New Perspectives on the Management of Moderate-to-Severe Atopic Dermatitis
Emma Guttman-Yassky, MD, PhD; Robert E. Kalb, MD; Jeffrey M. Weinberg, MD
Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis
New Perspectives on Managing a Chronic Inflammatory Disease
New Perspectives on the Management of Moderate-to-Severe Atopic Dermatitis
Pathophysiology to the Management of Moderate-to-Severe Disease
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates and Discussions About Pustular Disease Subtypes
Debates & Discussions on the Evolving Role of JAK Inhibitors
Collaborative Care for Better Patient Outcomes
Digging Deep on Shared Decision-Making
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
A Case-Based Update
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Best Practices for Diagnosis and Management
From Patient Evaluations to New Targeted Therapies
A Case-Based Update on Pediatric Patients
